Anti‑PD1 therapy in metastatic melanoma patients is associated with a high rate of cutaneous adverse events (AEs).[1] Atopic dermatitis (AD) is one of the AEs reported during therapy with pembrolizumab. Treatment of AD in cancer patients is challenging due to the limited availability of drugs. Dupilumab is a monoclonal antibody blocking IL‑4 and IL‑13 signalling.[2] Long‑term treatment with dupilumab in patients with moderate‑to‑severe AD has been shown to be safe and effective.
Atopic dermatitis onset in a Melanoma patient under Pembrolizumab therapy: a case of successful treatment with dupilumab / Tolino, E., Proietti, I., Skroza, N., Guardo, A.D., Fraia, M.D., Dybala, A., Potenza, C.. - In: INDIAN JOURNAL OF DERMATOLOGY. - ISSN 0019-5154. - 69:3(2024), pp. 268-269. [10.4103/ijd.ijd_123_23]
Atopic dermatitis onset in a Melanoma patient under Pembrolizumab therapy: a case of successful treatment with dupilumab
Tolino, Ersilia;Proietti, Ilaria;Skroza, Nevena;Guardo, Antonio Di;Fraia, Marco Di
;Dybala, Agnieszka;Potenza, Concetta
2024
Abstract
Anti‑PD1 therapy in metastatic melanoma patients is associated with a high rate of cutaneous adverse events (AEs).[1] Atopic dermatitis (AD) is one of the AEs reported during therapy with pembrolizumab. Treatment of AD in cancer patients is challenging due to the limited availability of drugs. Dupilumab is a monoclonal antibody blocking IL‑4 and IL‑13 signalling.[2] Long‑term treatment with dupilumab in patients with moderate‑to‑severe AD has been shown to be safe and effective.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tolino_atopic-dermatitis_2024.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
627.98 kB
Formato
Adobe PDF
|
627.98 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
